Clinical Trial Update: Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study evaluating magnesium iron hydroxycarbonate for hyperphosphataemia in haemodialysis patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Magnesium iron hydroxycarbonate (magnesium iron hydroxycarbonate)

Snippet

Sponsor: Ineos Healthcare Limited | Conditions: Chronic Kidney Failure | Phase 2 | Status: COMPLETED